Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.2, pp.123-135, 2015. ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1639, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, vol.387, pp.1540-1550, 2016. ,
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. The Lancet, vol.389, p.32517, 2017. ,
KEYNOTE-024: Phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as firstline therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1 (PD-L1), J Clin Oncol, vol.33, issue.15_suppl, pp.8103-8103, 2015. ,
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.379, issue.21, pp.2040-2051, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02345238
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer, N Engl J Med, vol.378, issue.22, pp.2078-2092, 2018. ,
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC, N Engl J Med, vol.378, issue.24, pp.2288-2301, 2018. ,
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma, N Engl J Med, vol.366, issue.10, pp.925-931, 2012. ,
PD-1 Restrains Radiotherapy-Induced Abscopal Effect, Cancer Immunol Res, vol.3, issue.6, pp.610-619, 2015. ,
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol, vol.18, issue.7, pp.895-903, 2017. ,
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.377, issue.20, pp.1919-1929, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01753457
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.379, issue.24, pp.2342-2350, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02284390
Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers: Opportunities and Challenges, Oncol Williston Park N, vol.22, issue.9, pp.1064-1084, 2008. ,
Radiotherapy and immunotherapy: a synergistic effect in cancer care, Med J Aust, vol.210, issue.1, pp.47-53, 2019. ,
Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Anti-Tumor Immune Responses via Cross-Presentation of Tumor Antigen, Cancer Immunol Res, vol.3, issue.4, pp.345-355, 2015. ,
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis, JAMA Oncol, vol.4, issue.2, pp.210-216, 2018. ,
Immunologically effective dose: a practical model for immuno-radiotherapy, Oncotarget, vol.9, issue.61, pp.31812-31819, 2018. ,
Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy, Cancer Res, vol.76, issue.17, pp.4931-4940, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01336779
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination, Am J Clin Oncol, p.1, 2018. ,
,
, Fabienne Palmerini, vol.2, p.4
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis, JAMA Oncol, vol.4, issue.2, pp.210-216, 2018. ,
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis, Lung Cancer Amst Neth, vol.134, pp.127-140, 2019. ,
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma, N Engl J Med, vol.366, issue.10, pp.925-931, 2012. ,
PD-1 Restrains Radiotherapy-Induced Abscopal Effect, Cancer Immunol Res, vol.3, issue.6, pp.610-619, 2015. ,
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol, vol.18, issue.7, pp.30380-30387, 2017. ,
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC, N Engl J Med, vol.379, issue.24, pp.2342-2350, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02284390
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy, Lancet Oncol, vol.16, issue.13, pp.498-509, 2015. ,
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.377, issue.20, pp.1919-1929, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01753457
Immunologically effective dose: a practical model for immuno-radiotherapy, Oncotarget, vol.9, issue.61, pp.31812-31819, 2018. ,
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination, Am J Clin Oncol, p.1, 2018. ,
, Legend : AE : adverse event, DCR disease control rate, PFS : progression free survival, OS : overall survival, HR : hazard ratio ; ICI : immune check point inhibitors, RT : radiotherapy , 95% CI : 95% confidence interval